Questcor Pharmaceuticals (QCOR) Slammed as Cerium Pharmaceuticals Granted FDA Orphan Drug Status
Tweet Send to a FriendGet Alerts QCOR Hot Sheet
Price: $37.61 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +40.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +40.7%
Trade QCOR Now!
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) is under heavy pressure early Friday which is related to reports Cerium Pharmaceuticals received FDA orphan drug designation for Synacthen Depot, the synthetic equivalent of Acthar.
Shares of QCOR last traded at $23.79, down 6.5 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of QCOR last traded at $23.79, down 6.5 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- OCZ Technology Group (OCZ) Active in Afternoon Trading
- The Hispanic Community is Not Happy with Herbalife (HLF)
Create E-mail Alert Related Categories
Trader TalkComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
thanks for adding to FRAUD
janie on Nov 3, 2012 11:25 AMMark as Spam | Reply to this comment
you are part of the Fraud that robs shareholders